GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Sai Parenterals Ltd

Sai Parenterals Q2 FY27 Consolidated Net Profit Rs. 10.5 crore; Acquisitions Completed

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 01 Nov 2026, 06:18 PM IST  ·  BSE ID: beff5d8b-5bc2-4d17-ab83-f6bf318d7f95
View Original BSE Filing (PDF)
💡
In Simple Terms
The pharmaceutical company announced quarterly profits and revenue, while also completing two acquisitions and expanding its production capacity.
🤖 AI Summary
  • Sai Parenterals reported Q2 FY27 consolidated net profit of Rs. 10.5 crore, with revenue of Rs. 196.1 crore.
  • Acquisition of 60% stakes in Saicriti Pharma and Prathyak Laboratories completed, utilizing Rs. 98.8 crore of IPO proceeds.
  • Unit III expansion at Bhongir completed, increasing production capacity by 81% from 85.5 to 155 million units monthly.
  • Noumed renewed Australian OTC supply agreements totaling AUD 232 million (approximately Rs. 1,506 crore).
  • New critical-care injectable facility at Gummadidala, under Saicriti Pharma, is targeted for July 2027 completion.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue From Operations (Consolidated) Q2 FY27
Rs. 196.1 crores
9.0%
Gross Profit (Consolidated) Q2 FY27
Rs. 93.1 crores
26.4%
PAT (Consolidated) Q2 FY27
Rs. 10.5 crores
32.7%
Gross Profit Margin (%) Q2 FY27
47.5%
EBITDA (Consolidated) Q2 FY27
Rs. 41.4 crores
67.4%
EBITDA Margin (%) Q2 FY27
21.1%
H1 FY27 Revenue From Operations (Consolidated)
Rs. 376.0 crores
H1 FY27 PAT (Consolidated)
Rs. 18.4 crores
🏢 How This Affects the Company
📈
Business Impact
The completed acquisitions of Saicriti Pharma and Prathyak Laboratories expand the company's critical care injectable capacity and consolidate R&D, with Sai Prathyak Laboratories beginning external CDMO development contracts from FY28. Renewal of Noumed's Australian OTC supply agreements for AUD 232 million enhances future revenue visibility and aims to shift from distribution to manufacturing margins.
💰
Financial Impact
Revenue from operations for Q2 FY27 reached Rs. 196.1 crore and PAT stood at Rs. 10.5 crore. Gross profit margin improved to 47.5% from 40.9% in Q1 FY27, reflecting tighter inventory management. Depreciation and amortisation increased to Rs. 25.1 crore due to asset capitalisation and consolidation activities.
⚙️
Operational Impact
Unit III expansion increases production capacity by 81% to 155 million units per month, with output ramping up from Q4 FY27. The new critical-care injectable facility under Saicriti Pharma is targeted for July 2027 completion, bringing injectable capacity to approximately 154.66 million units built to EU-GMP and USFDA standards. The Adelaide facility will begin operations in January 2027.
⚠️
Risk Impact
The note states that consolidated figures for Q2 & H1 FY27 include a full quarter of Noumed Pharmaceuticals, while Q2 & H1 FY26 do not due to consolidation effective November 12, 2025. This makes year-on-year comparisons not like-for-like.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results and business update.
👤
Who Is Affected
Shareholders are affected by the company's financial performance and strategic advancements, including the deployment of Rs. 98.8 crore of IPO proceeds for acquisitions, which impacts the company's asset base and future earnings potential.
🔍
Management Signal
Management's actions signal a focus on strategic acquisitions, capacity expansion, and improving operational efficiencies through inventory management and new ERP systems.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 results — monitor impact of Unit III expansion on output and revenue.
Saicriti Pharma facility update — track progress towards July 2027 commissioning target.
Adelaide facility operations — observe commercial supply commencement from April 2027.
MEDIUM RISK Year-on-year comparisons are not like-for-like due to acquisitions, making performance evaluation complex.
💡 Investor Takeaway
Sai Parenterals reported Q2 FY27 consolidated PAT of Rs. 10.5 crore on Revenue from Operations of Rs. 196.1 crore. Gross Profit Margin rose to 47.5% in Q2 FY27. The company confirmed completion of Saicriti Pharma and Prathyak Laboratories acquisitions and Unit III capacity expansion.
⚖️ Strengths & Concerns

✅ Positives

  • Q2 FY27 consolidated Gross Profit Margin improved to 47.5% from 40.9% in Q1 FY27, reflecting enhanced inventory management.
  • Unit III expansion completion increases production capacity by 81% to 155 million units a month, supporting Australian and New Zealand markets.

⚠️ Concerns

  • Depreciation and amortisation costs rose significantly to Rs. 25.1 crore in Q2 FY27 from Rs. 8.1 crore in Q1 FY27, impacting profitability.
  • Consolidated PAT Margin decreased to 5.4% in Q2 FY27 from 13.1% in Q2 FY26, as year-on-year comparisons are not like-for-like due to acquisition.
📅 Company Track Record
Sai Parenterals reported Q2 FY27 net profit of Rs. 105.10 Million in previous filings, along with the completion of Saicriti Pharma acquisition. The company's board met on November 1, 2026, to approve these Q2/H1 FY27 results and discuss acquisitions.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Sai Parenterals' consolidated net profit in Q2 FY27?
Sai Parenterals reported a consolidated Net Profit (PAT) of Rs. 10.5 crore for Q2 FY27.
What was Sai Parenterals' consolidated revenue from operations in Q2 FY27?
Consolidated Revenue from Operations for Sai Parenterals stood at Rs. 196.1 crore in Q2 FY27.
Which acquisitions did Sai Parenterals complete in Q2 FY27?
Sai Parenterals completed the acquisition of 60% stakes in Saicriti Pharma Private Limited and Prathyak Laboratories Private Limited, deploying Rs. 98.8 crore of IPO proceeds.
How much did Sai Parenterals' production capacity increase with the Unit III expansion?
The Unit III expansion increased Sai Parenterals' production capacity by 81%, from 85.5 to 155 million units a month.
What is the value of Noumed's renewed Australian OTC supply agreements?
Noumed renewed Australian OTC supply agreements valued at AUD 232 million, which is approximately Rs. 1,506 crore.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.